Eno, who joined HeartBeam as president in January 2023, takes over as part of a long-planned transition. Founder and CEO Branislav Vajdic intends to shift into the role of president following Eno’s move to the corner office. His focus now centers around further innovation, R&D and advancing AI applications.
Meanwhile, as CEO, Eno turns his focus to securing FDA 510(k) clearance for HeartBeam’s vector-based technology. Further responsibilities include preparation for commercialization and growth.
Santa Clara, California-based HeartBeam develops the AIMIGo as a credit card-sized, 12-lead 3D vector electrocardiogram (ECG) device. It developed the AIMI platform for acute care settings. AIMI provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.
Board Chair Rich Ferrari says the change at the top comes “at an important inflection point” as the company looks to leverage each leader’s strengths.
Eno brings three decades of experience including the creation of several go-to-market strategies for a range of breakthrough products.
Before HeartBeam, Eno served as CEO of Preview Medical, a diagnostic equipment company. Prior to that, he held the role of SVP for marketing at HeartFlow. Other roles held by Eno include senior marking and sales leadership positions at OptimMedica, NeoGuide Systems and Avantec Vascular.
“The HeartBeam technology is truly transformative and stands to change how cardiac care is managed in the future. We’ve only scratched the surface of unlocking new insights and understanding how our data-rich signals can benefit physicians and patients,” said Eno. “I am honored to lead the company at this exciting time and look forward to my continued partnership with Branislav as we evolve our business and technology to deliver on strategic objectives.”
